Cargando…
Mavrilimumab for severe COVID-19
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834396/ https://www.ncbi.nlm.nih.gov/pubmed/33521662 http://dx.doi.org/10.1016/S2665-9913(20)30307-6 |
| _version_ | 1783642271725387776 |
|---|---|
| author | Pourhoseingholi, Mohamad Amin Shojaee, Sajad Ashtari, Sara |
| author_facet | Pourhoseingholi, Mohamad Amin Shojaee, Sajad Ashtari, Sara |
| author_sort | Pourhoseingholi, Mohamad Amin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7834396 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78343962021-01-26 Mavrilimumab for severe COVID-19 Pourhoseingholi, Mohamad Amin Shojaee, Sajad Ashtari, Sara Lancet Rheumatol Correspondence Elsevier Ltd. 2020-11 2020-09-05 /pmc/articles/PMC7834396/ /pubmed/33521662 http://dx.doi.org/10.1016/S2665-9913(20)30307-6 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Pourhoseingholi, Mohamad Amin Shojaee, Sajad Ashtari, Sara Mavrilimumab for severe COVID-19 |
| title | Mavrilimumab for severe COVID-19 |
| title_full | Mavrilimumab for severe COVID-19 |
| title_fullStr | Mavrilimumab for severe COVID-19 |
| title_full_unstemmed | Mavrilimumab for severe COVID-19 |
| title_short | Mavrilimumab for severe COVID-19 |
| title_sort | mavrilimumab for severe covid-19 |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834396/ https://www.ncbi.nlm.nih.gov/pubmed/33521662 http://dx.doi.org/10.1016/S2665-9913(20)30307-6 |
| work_keys_str_mv | AT pourhoseingholimohamadamin mavrilimumabforseverecovid19 AT shojaeesajad mavrilimumabforseverecovid19 AT ashtarisara mavrilimumabforseverecovid19 |